Wed, August 24, 2011
Tue, August 23, 2011
Mon, August 22, 2011
Sat, August 20, 2011
Fri, August 19, 2011
Thu, August 18, 2011
Wed, August 17, 2011
[ Wed, Aug 17th 2011 ] - Market Wire
PPD???????BioDuro?????
Tue, August 16, 2011
Mon, August 15, 2011
Fri, August 12, 2011
Thu, August 11, 2011
Wed, August 10, 2011
Tue, August 9, 2011
Mon, August 8, 2011
Sun, August 7, 2011
Sat, August 6, 2011
Fri, August 5, 2011
Thu, August 4, 2011
Wed, August 3, 2011
Tue, August 2, 2011
Mon, August 1, 2011
Sun, July 31, 2011
Fri, July 29, 2011
Thu, July 28, 2011
Wed, July 27, 2011
[ Wed, Jul 27th 2011 ] - Market Wire
00 AM EDT
Tue, July 26, 2011
Mon, July 25, 2011
Sat, July 23, 2011
Fri, July 22, 2011
Thu, July 21, 2011

Dendreon Announces Webcast Presentation at Canaccord Genuity Growth Conference


//health-fitness.news-articles.net/content/2011/ .. tion-at-canaccord-genuity-growth-conference.html
Published in Health and Fitness on by Market Wire   Print publication without navigation


Dendreon Announces Webcast Presentation at Canaccord Genuity Growth Conference -- SEATTLE, Aug. 5, 2011 /PRNewswire/ --

Dendreon Announces Webcast Presentation at Canaccord Genuity Growth Conference

[ ]

SEATTLE, Aug. 5, 2011 /PRNewswire/ -- Dendreon Corporation (Nasdaq: [ DNDN ]) today announced that management will present at the Canaccord Genuity Growth Conference in Boston, MA on August 10 at 5:00 PM EDT.

The presentations will be webcast live and available for replay from Dendreon's website, [ www.dendreon.com ].  If you are unable to listen to the live webcasts, they will be archived on the site following the presentation. To access the replay, go to the Investor Relations section of the website.

Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development, commercialization and manufacturing of novel therapeutics. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy (ACI) product candidates designed to stimulate an immune response in a variety of tumor types. Dendreon's first product, PROVENGE® (sipuleucel-T), was approved by the U.S. Food and Drug Administration (FDA) in April 2010. Dendreon is exploring the application of additional ACI product candidates and small molecules for the potential treatment of a variety of cancers. The Company is headquartered in Seattle, Washington and is traded on the NASDAQ Global Market under the symbol DNDN. For more information about the Company and its programs, visit [ http://www.dendreon.com/ ].

SOURCE Dendreon Corporation

[ Back to top ]

RELATED LINKS
[ http://www.dendreon.com ]


Publication Contributing Sources